Health Canada authorisation of Radicava oral suspension for the treatment of amyotrophic lateral sclerosis
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. announced that Health Canada has granted market authorization for Radicava Oral Suspension, the oral formulation of Radicava V (edaravone), for the treatment of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease that currently has no cure and can progress rapidly